1,093 results
Page 22 of 55
6-K
eiim32
25 Apr 11
New Study Demonstrated Significant Reduction In Annualized Relapse Rate and Halting of Disability Progression In MS Patients Switching to Copaxone?
12:00am
6-K
bf8lse
12 Apr 11
Oral Laquinimod for Multiple Sclerosis Treatment Significantly Reduced Disease Activity and Disability Progression While Providing Good Safety and Tolerability
12:00am
6-K
7eb5yok0zpgkfpu
11 Apr 11
Teva Announces Presentation of New Data on Multiple Sclerosis and Parkinson???s Disease Treatments at 2011 American Academy of Neurology Annual Meeting
12:00am
6-K
81h0r
7 Apr 11
Teva and Oncogenex Present Preclinical Data on the Activity of Its Antisense Compound Custirsen (OGX-011/TV-1011) at the American Association of Cancer Research (Aacr) Annual Meeting 2011
12:00am
6-K
o7yioi3uhixxgi9dh
24 Mar 11
the Procter & Gamble Company and Teva Pharmaceutical Industries Form Consumer Health Care Partnership
12:00am
6-K
EX-5.3
1rogzdj 4jlsh
21 Mar 11
Current report (foreign)
12:00am
6-K
oylxp zq4oivvavcc9m
17 Mar 11
Teva Announces Pricing of $750,000,000 of Senior Notes
12:00am
424B5
fi9a3
17 Mar 11
Prospectus supplement for primary offering
12:00am
424B5
xhxql9dtzqzxi6ihxc5
16 Mar 11
Prospectus supplement for primary offering
12:00am
6-K
ya0g8ww6
1 Mar 11
Teva Announces Trial Date In Generic Copaxone? Litigation
12:00am
6-K
s9e8fj8933crw5x3v
9 Feb 11
Teva Announces Results from a Phase III Study for Qnaze??? Nasal Aerosol In Perennial Allergic Rhinitis
12:00am
6-K
ckeanq60jiqbt0knx
8 Feb 11
Teva Provides 2011 Non-gaap Financial Outlook
12:00am